Brokerages expect ABIOMED, Inc. (NASDAQ:ABMD) to report earnings of $0.93 per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for ABIOMED’s earnings. The lowest EPS estimate is $0.88 and the highest is $1.01. ABIOMED posted earnings of $0.70 per share in the same quarter last year, which would indicate a positive year over year growth rate of 32.9%. The firm is expected to issue its next quarterly earnings results on Thursday, February 7th.

On average, analysts expect that ABIOMED will report full year earnings of $5.04 per share for the current fiscal year, with EPS estimates ranging from $4.91 to $5.27. For the next year, analysts expect that the company will report earnings of $4.78 per share, with EPS estimates ranging from $4.55 to $5.50. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover ABIOMED.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, November 1st. The medical equipment provider reported $1.09 EPS for the quarter, topping the consensus estimate of $0.73 by $0.36. ABIOMED had a net margin of 27.60% and a return on equity of 20.09%. The business had revenue of $181.78 million for the quarter, compared to analyst estimates of $175.41 million. During the same quarter in the previous year, the firm posted $0.54 earnings per share. ABIOMED’s quarterly revenue was up 36.9% on a year-over-year basis.

ABMD has been the topic of several research reports. Morgan Stanley raised shares of ABIOMED from an “equal” rating to a “weight” rating and boosted their price objective for the stock from $396.00 to $496.00 in a research note on Wednesday, November 7th. BidaskClub raised shares of ABIOMED from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. ValuEngine raised shares of ABIOMED from a “hold” rating to a “buy” rating in a research note on Wednesday, November 28th. Finally, BTIG Research raised shares of ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 price objective on the stock in a research note on Friday, November 2nd. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $402.78.

In other ABIOMED news, VP Michael G. Howley sold 10,000 shares of ABIOMED stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $432.50, for a total value of $4,325,000.00. Following the completion of the transaction, the vice president now directly owns 48,954 shares of the company’s stock, valued at $21,172,605. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 3.50% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in ABIOMED by 5.9% in the third quarter. Vanguard Group Inc. now owns 4,647,227 shares of the medical equipment provider’s stock worth $2,090,091,000 after buying an additional 260,829 shares during the last quarter. BlackRock Inc. raised its holdings in shares of ABIOMED by 10.3% during the third quarter. BlackRock Inc. now owns 3,117,569 shares of the medical equipment provider’s stock valued at $1,402,127,000 after purchasing an additional 290,298 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of ABIOMED by 10.8% during the third quarter. Renaissance Technologies LLC now owns 1,719,023 shares of the medical equipment provider’s stock valued at $773,131,000 after purchasing an additional 167,600 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of ABIOMED by 193.5% during the third quarter. AQR Capital Management LLC now owns 1,207,996 shares of the medical equipment provider’s stock valued at $543,297,000 after purchasing an additional 796,482 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in shares of ABIOMED by 6.0% during the third quarter. Franklin Resources Inc. now owns 738,851 shares of the medical equipment provider’s stock valued at $332,281,000 after purchasing an additional 41,999 shares during the last quarter. 87.27% of the stock is owned by institutional investors and hedge funds.

NASDAQ:ABMD opened at $317.52 on Wednesday. ABIOMED has a one year low of $187.01 and a one year high of $459.75. The stock has a market cap of $15.00 billion, a P/E ratio of 107.76, a price-to-earnings-growth ratio of 2.72 and a beta of 0.28.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Featured Story: How does a reverse stock split work?

Get a free copy of the Zacks research report on ABIOMED (ABMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.